The Journal of clinical investigation · 2010
MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Denghong, Contu Riccardo, Latronico Michael V G, Zhang Jianlin, Rizzi Roberto, Catalucci Daniele, Miyamoto Shigeki, Huang Katherine, Ceci Marcello, Gu Yusu, Dalton Nancy D, Peterson Kirk L, Guan Kun-Liang, Brown Joan Heller, Chen Ju, Sonenberg Nahum, Condorelli Gianluigi
Аннотация
Mechanistic target of rapamycin (MTOR) plays a critical role in the regulation of cell growth and in the response to energy state changes. Drugs inhibiting MTOR are increasingly used in antineoplastic therapies. Myocardial MTOR activity changes during hypertrophy and heart failure (HF). However, whether MTOR exerts a positive or a negative effect on myocardial function remains to be fully elucidated. Here, we show that ablation of Mtor in the adult mouse myocardium results in a fatal, dilated cardiomyopathy that is characterized by apoptosis, autophagy, altered mitochondrial structure, and accumulation of eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). 4E-BP1 is an MTOR-containing multiprotein complex-1 (MTORC1) substrate that inhibits translation initiation. When subjected to pressure overload, Mtor-ablated mice demonstrated an impaired hypertrophic response and accelerated HF progression. When the gene encoding 4E-BP1 was ablated together with Mtor, marked improvements were observed in apoptosis, heart function, and survival. Our results demonstrate a role for the MTORC1 signaling network in the myocardial response to stress. In particular, they highlight the role of 4E-BP1 in regulating cardiomyocyte viability and in HF. Because the effects of reduced MTOR activity were mediated through increased 4E-BP1 inhibitory activity, blunting this mechanism may represent a novel therapeutic strategy for improving cardiac function in clinical HF.
Предметные рубрики MeSH
Adaptor Proteins, Signal TransducingAnimalsApoptosisCardiomegalyCardiomyopathy, DilatedCarrier ProteinsCell Cycle ProteinsCell SurvivalEukaryotic Initiation FactorsFemaleHeartMaleMechanistic Target of Rapamycin Complex 1MiceMice, Inbred C57BLMice, KnockoutMultiprotein ComplexesMyocardiumMyocytes, CardiacPhosphoproteinsPhosphorylationProteinsTOR Serine-Threonine KinasesTranscription Factors